Welcome to our dedicated page for Tandem Diabetes Care news (Ticker: TNDM), a resource for investors and traders seeking the latest updates and insights on Tandem Diabetes Care stock.
Tandem Diabetes Care, Inc. (symbol: TNDM) is a leading medical device company committed to enhancing the lives of individuals with diabetes through continuous innovation and a customer-first approach. Based in San Diego, California, Tandem focuses on the design, development, and commercialization of advanced insulin pump technologies.
The company's flagship products include the t:slim X2™ insulin pump, noted for its unique ability to receive remote feature updates via a personal computer, and the t:flex® insulin pump, which is tailored for patients with higher insulin requirements. These devices are designed to offer users greater flexibility, control, and ease of use, significantly improving diabetes management.
In addition to these main products, Tandem has introduced the Mobi pump, a smaller, more discreet device, and is actively working on developing a tubeless pump to further enhance user convenience and experience. The company's product portfolio generates substantial revenue from both the insulin pumps themselves and the accompanying disposable infusion sets, which need regular replacement every 2 to 3 days.
Approximately 75% of Tandem's total revenue comes from the U.S. market, with the remaining sales derived from other developed countries. The company's strong focus on innovation and user experience has cemented its position as a trusted name in diabetes care.
For the latest updates and relevant information about Tandem Diabetes Care, Inc., including recent achievements, ongoing projects, financial performance, and strategic partnerships, stay tuned to our news section.
Note: This description is for informational purposes only and is not intended for product support or medical advice. In case of a medical emergency, please dial 911. For immediate assistance with Tandem products, contact the 24-hour customer support team at 877-801-6901, pressing 1 twice.
Tandem Diabetes Care (TNDM) reported strong Q3 2024 financial results with worldwide GAAP sales increasing 31% to $244.0 million. The company achieved its highest quarterly sales in history, both domestically and internationally. Worldwide pump shipments grew by over 25% compared to Q3 2023, with approximately 21,000 pumps shipped in the US and nearly 11,000 internationally. The company demonstrated positive Adjusted EBITDA of $4.0 million (2% of sales) and returned to positive free cash flow. Despite these improvements, TNDM still reported a GAAP net loss of $23.3 million, though this was an improvement from the $33.0 million loss in Q3 2023.
Tandem Diabetes Care (TNDM) has announced its participation in multiple investor conferences in November 2024. The company will present updates at the UBS Global Healthcare Conference (Nov 14), Stifel Healthcare Conference (Nov 19), Jefferies London Healthcare Conference (Nov 20), and Wolfe Research Healthcare Conference (Nov 20). Additionally, they will host meetings at the Canaccord Genuity MedTech Forum (Nov 21). All presentations will be webcast live with 30-day archive access through Tandem's Investor Center website.
Tandem Diabetes Care, Inc. (NASDAQ: TNDM), a leading insulin delivery and diabetes technology company, has announced plans to release its third quarter 2024 financial results on Wednesday, November 6, 2024, after the financial markets close. The company will host a conference call and simultaneous webcast at 4:30 pm Eastern Time (1:30 pm Pacific Time) on the same day to discuss the results.
Investors and interested parties can access the live webcast of the call through Tandem Diabetes Care's Investor Center website. For those wishing to join by phone, a registration link is provided to obtain dial-in details and a personal pin. An archive of the webcast will be available for 30 days following the event on the company's Investor Center website.
Tandem Diabetes Care (NASDAQ: TNDM) has announced that its t:slim X2 insulin pump with Control-IQ automated insulin delivery technology is now compatible with Eli Lilly's Lyumjev ultra-rapid acting insulin in the European Union. This compatibility offers more flexibility for diabetes patients using Tandem's AID system in the EU.
A recent clinical study demonstrated high satisfaction and quality of life benefits when using Lyumjev with Control-IQ technology. Tandem and Lilly collaborated on this study and are working to secure Lyumjev compatibility for the t:slim X2 pump in other regions and for the Tandem Mobi pump.
Tandem Diabetes Care (Nasdaq: TNDM), a leading insulin delivery and diabetes technology company, has announced its participation in several upcoming investor conferences. The company will present updates and host meetings at the following events:
- 2024 Wells Fargo Healthcare Conference on September 5, 2024
- Morgan Stanley 22nd Annual Global Healthcare Conference on September 6, 2024
- Baird 2024 Global Healthcare Conference on September 11, 2024
- Lake Street Capital Markets 8th Annual Best Ideas Growth Conference on September 12, 2024
All presentations will be webcast live and archived for 30 days, accessible through Tandem Diabetes Care's Investor Center website.
Tandem Diabetes Care (Nasdaq: TNDM) has announced the release of version 2.8.2 of its Apple iOS t:connect mobile app on August 20, 2024. This update aims to address a battery depletion issue in t:slim X2 insulin pumps, which was the subject of a March 2024 recall. The problem can cause rapid battery drain, leading to unexpected pump shutdowns and potential health risks for users.
Key points:
- 143 confirmed adverse events, including two hospitalizations
- Update available in Apple App Store on August 20, 2024
- Impacted users urged to update their app immediately
- 24/7 technical support available for assistance
Tandem Diabetes Care (NASDAQ: TNDM) has provided an update on the March 2024 recall of its Apple iOS t:connect mobile app in the United States. The recall addresses an issue causing rapid depletion of t:slim X2 insulin pump batteries, potentially leading to unexpected pump shutdowns. Despite the release of version 2.7.1 in March, some customers continue to experience problems. 107 confirmed adverse events, including two hospitalizations, have been reported. Tandem plans to release a new app version to address remaining issues.
Recommendations for affected users include:
- Continue using the pump and app as per the User Guide
- Charge the pump daily for 10-15 minutes
- Monitor battery levels closely
- Carry backup supplies
- Charge immediately upon receiving a low battery alert
Tandem Diabetes Care (Nasdaq: TNDM) released its Q2 2024 financial results and raised its full-year 2024 sales guidance. Key highlights include:
Sales: Worldwide GAAP sales increased by 13% to $221.9M, while non-GAAP sales rose 12% to $221.8M compared to Q2 2023. US shipments of insulin pumps surged 33% sequentially. However, international shipments fell by 6%.
New Products: The company launched the Tandem Mobi integrated with the Dexcom G7 CGM in the US and began the international rollout of Tandem Source. Additionally, enrollment for the Control-IQ pivotal study for type 2 diabetes was completed.
Financials: GAAP gross profit increased to $112.8M from $101.7M. However, the GAAP operating loss was $30.8M, and the GAAP net loss was $30.8M. Non-GAAP operating loss stood at $30.9M, and non-GAAP net loss was $30.9M.
Guidance: The company increased its full-year 2024 sales guidance, reflecting strong demand for its latest technologies.
Tandem Diabetes Care (Nasdaq: TNDM), a leading insulin delivery and diabetes technology company, has announced its participation in the Canaccord Genuity 44th Annual Growth Conference. The company's management will present an update on Tuesday, August 13, 2024, at 1:30 PM Eastern Time (10:30 AM Pacific Time).
The presentation will be webcast live and an archive recording will be available for 30 days afterwards. Interested parties can access the live webcast and archive through the 'Events & Presentations' section of Tandem Diabetes Care's Investor Center website at http://investor.tandemdiabetes.com.
Tandem Diabetes Care and Dexcom have announced that the t:slim X2 insulin pump with Dexcom G7 CGM compatibility has been authorized for sale by Health Canada. This integration makes it the only Automated Insulin Delivery (AID) system in Canada compatible with both Dexcom G7 and G6 CGM technologies. The updated software is expected to be commercially available this fall, with existing users receiving a free remote update.
Key features of the integration include:
- Dexcom G7's smaller, all-in-one sensor and transmitter
- 30-minute sensor warmup time
- 12-hour grace period for sensor replacement
- Increased connectivity with digital health apps
The t:slim X2 pump with Control-IQ technology is rated as the #1 AID system in Canada, offering customizable profiles and various infusion set options.
FAQ
What is the current stock price of Tandem Diabetes Care (TNDM)?
What is the market cap of Tandem Diabetes Care (TNDM)?
What is Tandem Diabetes Care, Inc. known for?
Where is Tandem Diabetes Care, Inc. located?
What are the main products of Tandem Diabetes Care, Inc.?
How do the t:slim X2™ insulin pump updates work?
What percentage of Tandem Diabetes Care's revenue comes from the U.S.?
Does Tandem Diabetes Care offer customer support?
What recent products has Tandem Diabetes Care introduced?
What materials are required to replace in Tandem's insulin pumps?
What is the unique feature of the t:flex® insulin pump?
How does Tandem Diabetes Care innovate in diabetes care?
